

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 27, 2012

000-53446

(Commission File Number)

PROPANC HEALTH GROUP CORPORATION
(Exact name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

33-0662986
(I.R.S. Employer
Identification No.)

576 Swan Street
Richmond, VIC, 3121 Australia
(Address of principal executive offices) (Zip Code)

61 03 92084182

(Registrant's telephone number, including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Forward-Looking Statements

Statements in this Current Report on Form 8-K (including the exhibit) that are not purely historical facts, including statements regarding Propanc's beliefs, expectations, intentions or strategies for the future, may be "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the plans, intentions and expectations reflected in or suggested by the forward-looking statements. These risks and uncertainties include Propanc's entry into new commercial businesses, the risk of obtaining financing, recruiting and retaining qualified personnel, and other risks described in Propanc's Securities and Exchange Commission filings. The forward looking statements in this Form 8-K speak only as of the date hereof, and Propanc disclaims any obligation to provide updates, revisions or amendments to any forward looking statement to reflect changes in the Propanc's expectations or future events.

Item 8.01 Other Events

On June 27, 2012, Propanc Health Group Corporation (the "Company") issued a press release announcing that its 15c2-11 application was approved by the Financial Industry Regulatory Authority and its shares of common stock will trade on the Over-the-Counter Bulletin Board under the ticker symbol "PPCH".

A copy of the press release titled, "Propanc to Begin Trading on the OTC Bulletin Board Under the Symbol PPCH" is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

9.01 (d) Exhibits

99.1 Press Release titled, "Propanc to Begin Trading on the OTC Bulletin Board Under the Symbol PPCH", dated June 26, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

PROPANC HEALTH GROUP CORPORATION

Dated: June 27, 2012

By: /s/ James Nathanielsz

Name: James Nathanielsz

Title: Chief Executive Officer



Propanc to Begin Trading on the OTC Bulletin Board Under the Symbol PPCH

MELBOURNE, Australia, June 27, 2012 – Propanc Health Group Corporation (OTCBB: PPCH), a developmental stage healthcare company focused on the development of new cancer treatments for patients with solid tumors, announced today that its 15c2-11 application was approved by the Financial Industry Regulatory Authority and its shares of Common Stock will trade on the OTC Bulletin Board under the ticker symbol “PPCH.”

James Nathanielsz, CEO of Propanc, commented, “We have reached a point in the development of our pro-enzyme cancer treatments that makes now the most optimal time to launch Propanc into the investor market. The need for an alternative to today’s existing cancer treatments has never been greater and the success we have achieved during preclinical trials in inhibiting tumor growth and stopping its spread, specifically within patients with pancreatic and colorectal cancer, demonstrates the vast potential our patented, pro-enzyme formulations will have in the healthcare industry.”

About Propanc Health Group Corporation

Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions.

Propanc’s leading products, PRP and PRP-DCM, are novel, patented suppository formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects, Propanc intends to progress PRP and/or PRP-DCM along the rigorous, formal non-clinical and clinical development pathway required to obtain regulatory approval to market its proenzyme formulation. Propanc intends to undertake development of manufacturing, formal non-clinical studies and then Phase I, II and III clinical trials in order to generate the quality, safety and efficacy data required for regulatory approval.

Forward-looking Statements:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the company's most recent Quarterly Report on Form 10-Q and related 8-K filings.

Investor Relations Contact:

Stanley Wunderlich
Consulting for Strategic Growth 1 Ltd.
Tel: 800-625-2236 ext. 7770
Email: info@cfsg1.com